Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M.
Di Leo A, et al. Among authors: malorni l.
J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.
J Natl Cancer Inst. 2014.
PMID: 24317176
Free PMC article.
Clinical Trial.